Streetbeat News

VNRX

VolitionRx Limited

https://www.volition.com

Industry

Medical - Diagnostics & Research

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.

Open

0.62

Mkt cap

60M

Volume

194K

High

0.62

P/E Ratio

-1.72

52-wk high

1.10

Low

0.58

Div yield

N/A

52-wk low

0.43

VolitionRx Limited (NYSE AMERICAN: VNRX) is showcasing its Nu.Q® Vet Cancer Test at the 97th Annual Western Veterinary Conference, a major event for veterinary professionals.

Portfolio Pulse from

February 28, 2025 | 1:45 pm

VolitionRx Limited has announced its first commercial sale of its High Throughput Synthetic Sepsis method, which measures NETs activation and inhibition in real time. This marks an expansion of their commercial offerings and they are in discussions with pharmaceutical companies.

Portfolio Pulse from

February 06, 2025 | 1:45 pm

VolitionRx Limited (NYSE AMERICAN: VNRX) will host a virtual investor event on February 14, 2025, focusing on their Nu.Q® NETs product for sepsis management.

Portfolio Pulse from

February 05, 2025 | 2:30 pm

VolitionRx Limited announced that its Nu.Q® NETs H3.1 biomarker is an independent predictor of 28-day mortality in sepsis patients, potentially impacting its stock positively.

Portfolio Pulse from

January 30, 2025 | 1:45 pm

VolitionRx Limited, a multi-national epigenetics company, released its Business Review for 2024, highlighting key achievements from the past year.

Portfolio Pulse from

January 08, 2025 | 1:45 pm

VolitionRx Limited announced that its Nu.Q® Lung Cancer Test successfully differentiated between malignant and benign nodules in a large-scale study, enhancing the diagnostic process for lung cancer patients.

Portfolio Pulse from

December 10, 2024 | 1:15 pm

VolitionRx Limited has announced a registered direct offering, raising up to $1.9 million initially, with potential additional proceeds of $2.7 million from warrant exercises. The offering includes shares sold to insiders and other investors, with warrants exercisable immediately.

Portfolio Pulse from

December 06, 2024 | 2:15 pm

VolitionRx Limited (VNRX) held its Q3 2024 earnings call, discussing company performance and future outlook. Key participants included executives and analysts from various firms.

Portfolio Pulse from

November 15, 2024 | 5:00 pm

VolitionRx Limited has announced its third quarter 2024 financial results and will hold a conference call to discuss these results on November 15, 2024.

Portfolio Pulse from

November 14, 2024 | 9:30 pm

VolitionRx Limited has scheduled its third quarter 2024 earnings conference call and business update for November 15, 2024, at 8:30 a.m. U.S Eastern Time.

Portfolio Pulse from

November 08, 2024 | 1:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.